Bevacizumab (Avastin) for Stage 3 Retinopathy of Prematurity – In Zone I or Posterior Zone II (2010) Helen Mintz-Hittner

Description

This article reviews the role of anti-vascular endothelial growth factor (anti-VEGF) therapy using Bevacizumab (Avastin) for treating stage 3 Retinopathy of Prematurity (ROP) in high-risk zones. It discusses the problems associated with conventional laser therapy, defines the specific advantages and potential complications of using Bevacizumab, and advocates for its potential as a first-line treatment.